Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04214886 · ClinicalTrials.gov registry record · Phase 1
CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies
A Phase 1 study of B-Cell Acute Lymphoblastic Leukemia, Adult and B-cell Lymphoma Refractory, sponsored by Loyola University.
- Active
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT04214886: Active Phase 1 study of B-Cell Acute Lymphoblastic Leukemia, Adult and B-cell Lymphoma Refractory, sponsored by Loyola University.
NCT04214886 is a Phase 1 study of B-Cell Acute Lymphoblastic Leukemia, Adult and B-cell Lymphoma Refractory that is active but no longer recruiting, run by Loyola University. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04214886, a Phase 1 study of B-Cell Acute Lymphoblastic Leukemia, Adult and B-cell Lymphoma Refractory, is active but no longer recruiting, sponsored by Loyola University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
In this protocol, the investigators hypothesize that modifying the process of producing CAR+ T-cells can help to improve responses and reduce toxicities. Building on previous in vitro studies that have shown successful production of CAR+ T-cells using a new production approach, the investigators are now studying the ability to produce these CAR+ T-cells and determine how well they work in the clinical setting.
Primary Outcome
24 participants evaluated for determination of the feasibility of producing CD19-CD34 CAR T cells meeting the established release criteria
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL CD19-CD34 CAR transduced T cells
Study Locations (1)
Illinois
- Loyola University - Maywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-12-31 |
| Est. Completion | 2034-12-31 |
| Phase | Phase 1 |
What the registry record for NCT04214886 still lists
NCT04214886 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 3 conditions, with B-Cell Acute Lymphoblastic Leukemia, Adult appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT04214886 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT04214886 about?
NCT04214886 is a clinical study titled "CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies". In this protocol, the investigators hypothesize that modifying the process of producing CAR+ T-cells can help to improve responses and reduce toxicities. Building on previous in vitro studies that have shown successful production of CAR+ T-cells using a new production approach, the investigators are...
What is the current status of trial NCT04214886?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2019-12-31. Estimated completion is 2034-12-31.
What conditions does trial NCT04214886 study?
This clinical trial studies the following conditions: B-Cell Acute Lymphoblastic Leukemia, Adult, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent.
What interventions are being tested in trial NCT04214886?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), CD19-CD34 CAR transduced T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04214886?
This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04214886 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-Cell Acute Lymphoblastic Leukemia, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04214886's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI